ALK and non-small cell lung carcinoma: The efficacy and safety of crizotinib for the treatment of patients metastatic NSCLC with ALK rearrangements, who had not received previous systemic treatment, were demonstrated in a global, randomized, open-label PROFILE 1014 study.